Sol-Gel Technologies Ltd. Share Price

Equities

SLGL

IL0011417206

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 10/05/2024 BST 5-day change 1st Jan Change
0.6983 USD -6.27% Intraday chart for Sol-Gel Technologies Ltd. -17.89% -36.81%
Sales 2024 * 2.4M 192M Sales 2025 * 6.1M 487M Capitalization 19.45M 1.55B
Net income 2024 * -19M -1.52B Net income 2025 * -14M -1.12B EV / Sales 2024 * 8.11 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 3.19 x
P/E ratio 2024 *
-1 x
P/E ratio 2025 *
-1.7 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.83%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Sol-Gel Technologies Ltd.

1 day-6.27%
1 week-17.89%
Current month-1.99%
1 month-16.88%
3 months-46.28%
6 months-49.40%
Current year-36.81%
More quotes
1 week
0.63
Extreme 0.6311
0.81
1 month
0.63
Extreme 0.6311
1.05
Current year
0.63
Extreme 0.6311
1.58
1 year
0.63
Extreme 0.6311
4.05
3 years
0.63
Extreme 0.6311
14.50
5 years
0.00
Extreme 0
21.00
10 years
0.00
Extreme 0
21.00
More quotes
Managers TitleAgeSince
Founder 62 27/10/97
Director of Finance/CFO 56 31/01/17
Chief Operating Officer 48 31/12/09
Members of the board TitleAgeSince
Director/Board Member 55 25/07/23
Director/Board Member 50 12/09/18
Chairman 69 31/12/13
More insiders
Date Price Change Volume
10/05/24 0.6983 -6.27% 5,341
09/05/24 0.745 +2.31% 7,791
08/05/24 0.7282 -2.91% 38,920
07/05/24 0.75 -8.55% 53,279
06/05/24 0.8201 -3.56% 6,439

Delayed Quote Nasdaq, May 10, 2024 at 09:00 pm

More quotes
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.6983 USD
Average target price
8 USD
Spread / Average Target
+1,045.64%
Consensus